<DOC>
	<DOCNO>NCT01680159</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety pharmacokinetics TA-650 increase dose 10 mg/kg every 8 week patient psoriasis effect treatment confirm treatment Remicade® 5 mg/kg every 8 week decrease thereafter .</brief_summary>
	<brief_title>A Clinical Study Increased Dose TA-650 Patients With Psoriasis</brief_title>
	<detailed_description>- Patients plaque psoriasis psoriatic arthritis : 1 . Screening Period : TA-650 5 mg per kg body weight administered day TA-650 administration start ( week 0 ) week 8 ( efficacy judge decrease maintain week 8 screening period ) , respectively , intravenous infusion slowly least 2 hour . 2 . Increased Dose Period : If efficacy judge decreased screening period , TA-650 10 mg per kg body weight administered day TA-650 administration start ( week 0 ) every 8 week week 32 increase dose period , respectively , one dose intravenous infusion slowly least 2 hour . - Patients pustular psoriasis psoriatic erythroderma : TA-650 10 mg per kg body weight administered day TA-650 administration start ( week 0 ) every 8 week week 32 , respectively , one dose intravenous infusion slowly least 2 hour .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Dermatitis , Exfoliative</mesh_term>
	<criteria>Patients already diagnose plaque psoriasis , psoriatic arthritis , pustular psoriasis ( exclude localize ) , psoriatic erythroderma . Patients effect treatment confirm certain period start administration Remicade® 5 mg/kg every 8 week decrease thereafter . Patients guttate psoriasis . Patients druginduced psoriasis Patients previously use biological product infliximab . Patients concomitant diagnosis , history within 6 month prior provisional enrollment , serious infection need hospitalization . Patients concomitant diagnosis , history within 6 month prior provisional enrollment , opportunistic infection Female patient pregnant , breastfeeding , possibly pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Infliximab</keyword>
	<keyword>REMICADE</keyword>
	<keyword>TA-650</keyword>
	<keyword>psoriasis</keyword>
</DOC>